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ABSTRACT
Extensive tissue remodeling mediated by matrix metalloproteases (MMPs) is 
an important part of cancer. The aim of this study was to investigate whether serum 
biomarkers reflecting MMP-mediated degradation of type I collagen (C1M), type IV 
collagen (C4M) and citrullinated vimentin (VICM) were predictive of cancer-specific 
mortality. Between 1999 and 2001, 5855 Danish postmenopausal women participated 
in The Prospective Epidemiologic Risk Factor (PERF I) study. Demographics and serum 
samples were collected at enrolment. Cancer diagnosis, and cause and time of death 
were obtained from Danish registries. C1M, C4M and VICM were measured by ELISA. 
Hazard ratios (HR) and Kaplan-Meier curves were applied to assess mortality at 3 and 
12 years of follow-up for women diagnosed with cancer within 3 years from blood 
sampling. Within 3 years from blood sampling, 250 women had been diagnosed with 
cancer. C1M and VICM were associated with survival over time at 3 years of follow-up. 
Only C1M was predictive of mortality at 3 years follow-up: the adjusted HR was 2.65 
[95% CI: 1.08-6.51]. In conclusion, C1M and VICM are associated with survival in 
postmenopausal women with cancer, and C1M is an independent risk factor for cancer-
specific mortality. Thus, quantification of tissue remodeling is important in cancer.
INTRODUCTION
A major contributor to mortality in the elderly 
population is age-related diseases such as cancer [1, 2]. 
It is therefore an important health priority to identify risk 
factors for cancer related death in individuals suffering 
from this disease. Biomarkers for risk assessment may 
contribute directly to the identification of high-risk 
subgroups of a population and contribute to understanding 
the etiology of cancer in more detail [3]. Moreover, such 
risk factor biomarkers may have a direct impact on clinical 
decision-making and hence have a significant influence on 
overall outcome.
An important part of the malignant changes in 
cancer is extensive tissue remodeling. Importantly, the 
extracellular matrix (ECM) composition changes and 
becomes uncontrolled [4]. The ECM is the non-cellular 
component of all tissues and organs and is divided into the 
basement membrane and the underlying interstitial matrix. 
The ECM is constantly being modified and remodeled 
through protein synthesis and secretion, enzymatic 
degradation, and post-translational modifications [5].
In tumors the ECM interacts with cells and regulates 
diverse functions associated with malignancy. It is becoming 
widely accepted that signals from the ECM affects directly 
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the hallmarks of cancer [6]. Hence, any ECM dysregulation 
may be part of the changes that drive cancer [7].
ECM remodeling in cancer is characterized both 
by an increased and altered production of ECM proteins 
(desmoplasia), as well as an increased and altered degradation 
of ECM proteins in the presence of proteases such as matrix 
metalloproteases (MMPs) [8]. Our research group has 
previously developed a technology enabling non-invasive 
assessment of MMP-mediated type I collagen degradation 
(C1M) [9] and MMP-mediated type IV collagen degradation 
(C4M) [10]. Elevated levels of C1M and C4M have been 
observed in serum from patients with malignant diseases of 
the lung, breast, ovary and pancreas [11–13]. Type I collagen 
and type IV collagen are the main components of interstitial 
matrix and basement membrane, respectively.
Using the same technology as for C1M and C4M, 
assessment of MMP-degraded and citrullinated vimentin 
(VICM) [14] has been found elevated in serum from lung 
cancer patients [12]. Vimentin is an intermediate filament 
protein. It is released from activated stromal cells [15] 
and expressed on the surface of cancer cells [16] making 
it a possible MMP substrate and target for citrullination 
by peptidylarginine deiminase (PAD) which are activated 
during inflammation and cancer [17].
Recently C1M was shown to be predictive of 
mortality in a large observational study of postmenopausal 
women, the Prospective Epidemiological Risk Factor 
(PERF I) study [18]. The best predictive value of C1M 
was for cancer-specific mortality, the most prevalent cause 
of death. Interestingly, it was also recently shown in the 
PERF I cohort, that C1M, C4M, and VICM were elevated 
in those women that were subsequently diagnosed with 
cancer and that C1M and VICM were both independent 
predictors of increased risk of developing cancer [19]. It 
remains to be determined if the predictive value of C1M 
for cancer-specific mortality also applies to women given 
a cancer diagnosis within the same vicinity of time, as 
well as it remains to be determined if C4M and VICM 
predicts cancer-specific mortality in this cohort. In this 
study, we sought to determine if C1M, C4M and VICM 
was predictive of cancer-specific mortality in the subgroup 
of women in the PERF I study who were diagnosed with 
cancer shortly after PERF I enrolment, i.e. within 3 years 
from blood sampling.
RESULTS
Cohort definition and baseline characteristics
The study design and women included and excluded 
from analysis are summarized in Figure 1. In total, 34% 
Figure 1: Cohort and study design. Overview of women included and excluded from analysis. *Excluded were those diagnosed with 
a benign neoplasm: ICD10 codes D10-D36; neoplasms of uncertain or unknown behavior: ICD10 codes D37-D48; skin cancer: ICD-10 
codes C44, D040-D049 (i.e. not including malignant melanoma); dysplasia: ICD-10 code N87; non-solid tumors: ICD-10 codes C81-C96 
(a.k.a. malignant neoplasms stated or presumed to be primary, of lymphoid, hematopoietic and related tissue). External CoD: ICD-10 codes 
V01-Y98; Cancer CoD: ICD10 codes C00-D48. CoD =cause of death.
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(n=1985) of the women participating in PERF I were 
diagnosed with cancer at any time between 1947 and 
2012, the latest date recorded in the Danish registries. Of 
the women diagnosed with cancer after PERF I enrollment 
(n=881), 28% (n=250) were diagnosed within the first 3 
years. This cohort of women was used to investigate 
survival in the first 3 years from blood sampling and in the 
entire follow-up period of approximately 12 years. Of the 
250 women diagnosed in the first 3 years, 29% (n=72) died 
within the first 3 years. In 99% of these (n=71), cancer was 
registered as the CoD. During the entire 12-year follow-
up, 62% (n=155) died in total with 83% (n=129) having 
cancer registered as the CoD.
The characteristics of the women diagnosed with 
cancer within the first 3 years from baseline are summarized 
in Table 1. The women are stratified as ‘alive’, ‘dead by 
all-cause mortality’ and ‘dead by cancer-specific mortality. 
Details are outlined for 3 and 12 years’ follow-up.
Overall characteristics of the cancer diagnoses in 
the cohort
The most prevalent cancers were malignant 
neoplasms of the digestive organs (ICD-10 codes 
C15-C26), the respiratory and intra-thoracic organs (ICD-
10 codes C30-C39), the breast (ICD-10 codes C50) and 
the female genital organs (ICD-10 codes C51-C58), which 
together accounted for 76% of all diagnoses within the first 
3 years from baseline. In the 250 women diagnosed within 
the first 3 years, a total of 253 diagnoses were registered. 
Of these, 115 were defined as local disease, 76 as lymph 
node-positive, 42 as metastatic and 19 as unknown. 
Median biomarker levels did not differ significantly 
between localized cancers and those in later stages (data 
not shown). More localized cancers and less metastatic 
cancer were found in the women still alive than in those 
who died. Significantly fewer days from baseline to 
Table 1: Cohort characteristics of women diagnosed with cancer within the first three years from baseline for 3 and 
12 years of follow-up
Variable
Total
n=250
3 year follow-up 12 year follow-up
Alive
n=178
Dead (All)
n=72
p-value
vs. Alive
Dead (Cancer)
n=71
p-value
vs. Alive
Alive
n=95
Dead (All)
n=155
p-value
vs. Alive
Dead (Cancer)
n=129
p-value
vs. Alive
Age at baseline  
(years)
72.5
[71.3-73.8]
(250)
72.4
[71.0-73.8]
(178)
73.0
[70.9-75.5]
(72)
0.214
73.1
[71.1-75.6]
(71)
0.116
71.3
[69.9-72.5]
(95)
73.8
[72.0-75.1]
(155)
0.004
73.2
[71.3-74.7]
(129)
0.014
BMI (≥25)
55 %
(133/241)
60 %
(104/173)
43 %
(29/68) 0.021
42 %
(28/67) 0.016
61 %
(57/93)
51 %
(76/148) 0.168
51 %
(62/122) 0.164
Smoking 27 %
(68/250)
24 %
(42/178)
36 %
(26/72) 0.063
37 %
(26/71) 0.054
21 %
(20/95)
31 %
(48/155)
0.118 29 %(37/129) 0.254
Alcohol  
(≥7 drinks/week)
36 %
(89/249)
35 %
(62/177)
38 %
(27/72) 0.823
38 %
(27/71) 0.765
35 %
(33/94)
36 %
(56/155)
0.979 39 %
(50/129)
0.677
Exercise  
(≥1 time/week)
65 %
(162/249)
70 %
(124/177)
53 %
(38/72) 0.014
52 %
(37/71) 0.011
68 %
(64/94)
63 %
(98/155)
0.521 62 %(80/129) 0.427
Education:
Primary 
school
High 
school
University
73 %
(183/249)
21 %
(51/249)
6 %
(15/249)
75 %
(132/177)
18 %
(33/177)
7 %
(12/177)
71 %
(51/72)
25 %
(18/72)
4 %
(3/72)
0.430
70 %
(50/71)
25 %
(18/71)
5 %
(3/71)
0.411
72 %
(68/94)
18 %
(17/94)
10 %
(9/94)
74 %
(115/155)
22 %
(34/155)
4 %
(6/155)
0.164
72 %
(93/129)
24 %
(31/129)
4 %
(5/129)
0.157
Hypertension 6 %
(15/250)
7 %
(12/178)
4 %
(3/72) 0.630
4 %
(3/71) 0.647
5 %
(5/95)
6 %
(10/155)
0.913 7 %(9/129) 0.807
Hyperlipidemia 35 %(88/249)
39 %
(69/178)
27 %
(19/71) 0.101
26 %
(18/70) 0.073
40 %
(38/95)
32 %
(50/154)
0.184 30 %(39/128) 0.181
HRT 23 %
(57/250)
24 %
(42/178)
21 %
(15/72)
0.760 21 %
(15/71)
0.801 26 %
(25/95)
21 %
(32/155)
0.378 20 %(26/129) 0.355
C1M (ng/ml)
42.9
[39.1-47.5]
(238)
40.9
[38.2-45.8]
(171)
47.3
[38.4-54.8]
(67)
0.080
46.8
[38.4-53.3]
(66)
0.092
42.9
[38.8-50.5]
(91)
42.3
[38.1-47.8]
(147)
0.561
43.8
[38.3-48.9]
(121)
0.971
C4M (ng/ml)
71.9
[68.6-75.8]
(238)
73.2
[68.7-76.2]
(171)
69.2
[66.4-78.6]
(67)
0.975
69.1
[66.4-78.6]
(66)
0.806
75.3
[70.7-79.2]
(91)
71.0
[66.3-75.6]
(147)
0.127
69.0
[66.1-76.9]
(121)
0.160
VICM (ng/ml)
3.9
[3.60-4.30]
(238)
3.60
[3.12-4.00]
(171)
4.70
[3.90-6.10]
(67)
0.002
4.75
[3.96-6.14]
(66)
0.002
3.80
[3.37-4.10]
(91)
3.90
[3.43-4.70]
(147)
0.578
4.00
[3.62-4.80]
(121)
0.463
Data are shown as either median with 95% CI in brackets or as percentage. Absolute numbers shown in parentheses (cases/total).
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diagnosis were observed in the deceased group compared 
with those still alive at 12 years follow-up whereas no 
difference was detected at 3 years follow-up. Finally, of 
the 250 women diagnosed within the first 3 years, 16% 
(n=41) had a cancer diagnose registered prior to PERF I.
Variables as predictors of cancer-specific 
mortality within 3 years and 12 years from 
baseline
The individual ability of C1M, C4M, VICM and 
common risk factors to predict cancer-specific mortality 
at 3 years and 12 years of follow-up, are shown in Table 
2 which summarizes HRs with 95% CIs calculated from 
univariable Cox proportional-hazard regression models. At 
3 years follow-up, C1M and VICM, but not C4M, were 
predictive of cancer-specific mortality when dividing the 
biomarkers into quartiles. BMI, smoking and exercise 
were the only secondary risk factors associated with 
cancer-specific mortality at 3 years follow-up. At 12 years 
follow-up, none of the 3 biomarkers were associated with 
cancer specific mortality; only age and smoking were 
associated with cancer-specific mortality at 12 years 
follow-up.
To address the potential independent predictive 
value of C1M, C4M and VICM for cancer-specific 
mortality, a multivariable Cox proportional-hazard 
regression model was used to calculate HR for the 
biomarkers divided into quartiles and including the 
secondary risk factors listed in Table 2. The HRs with 95% 
CIs are illustrated in Figure 2, and details of all variables 
in the model are summarized in Table 3. At 3 years’ 
follow-up, only C1M was independently associated with 
cancer-specific mortality. The risk was stepwise increased 
with increasing quartile and women having the highest 
C1M levels (Q4) had a 2.65-fold (HR=2.65) higher risk of 
cancer-specific mortality than the women with the lowest 
C1M levels (Q1). In contrast, neither VICM nor C4M was 
independently associated with cancer-specific mortality. 
At 12 years’ follow-up none of the three biomarkers were 
independently associated with cancer-specific mortality. 
Moreover, none of the three markers were independently 
associated with cancer-specific mortality when analyzed 
on a continuous scale (data not shown).
Association between C1M, C4M and VICM 
levels, and survival over time
Kaplan-Meier survival curves illustrate cancer-
specific mortality over time for the three biomarkers 
analyzed (Figure 3). Only women with biomarker levels 
in Q1 and Q4 were compared. At 3 years’ follow-up, a 
significant difference was detected in the survival curves 
for C1M (p=0.022) and VICM (p=0.002) but not for C4M 
(p=0.773). No significant difference was detected for the 
entire follow-up period.
DISCUSSION
In this study we investigated whether the serum-
based biomarkers of MMP-degraded type I collagen 
(C1M), MMP-degraded type IV collagen (C4M) and 
MMP-degraded citrullinated vimentin (VICM) were 
associated with cancer-specific mortality in a cohort of 
postmenopausal women diagnosed with cancer within 3 
years from blood sampling. For both C1M and VICM, 
the women with the highest biomarker levels (Q4) had a 
significantly lower survival rate within the first 3 years 
of follow-up as compared to women having the lowest 
biomarker levels (Q1). However, only C1M, but not 
VICM, was able to independently predict cancer-specific 
mortality in this cohort. The predictability for C1M only 
applied to the outcome 0-3 years after blood sampling, and 
not 0-12 years after blood sampling, indicating that C1M 
could reflect ongoing progressive cancer-related activity.
C1M is the sum of increased type I collagen 
production and degradation and could be regarded as 
a marker of more active ECM or interstitial matrix 
remodeling. C1M could be regarded as a potential 
surrogate measure of a specific desmoplastic event and 
increased proteolytic (MMP) activity degrading type 
I collagen. Moreover, type I collagen have been shown 
to be degraded by MMPs as part of cell invasion and 
morphogenesis in vitro [20]. It is also well established 
that interstitial collagenases (MMPs) are associated with a 
poor prognosis in a variety of cancers [21].
The lack of ability to detect an association 
between C4M and cancer-specific mortality may seem 
counterintuitive, as basement membrane degradation, 
producing C4M is typically associated with tumor/
epithelial cell invasion and metastasis, which again is 
associated with a poorer outcome than localized tumors. 
It is possible that other basement membrane degradation 
products will be associated with cancer progression and 
mortality in the present study.
The fact that relatively high C1M levels prior to 
diagnosis are associated with mortality indicates that 
interstitial matrix damage may lead to a more tumor-
progressive stromal environment. Interestingly, different 
studies indicate that the underlying stroma, which 
includes the interstitial matrix, rather than the epithelium, 
is the target of carcinogens. In one example, a malignant 
transformation of epithelial cells occurred only when 
the stroma was exposed in vivo to a carcinogen [22]. In 
another example, when epithelial cells were transplanted 
into irradiated BALB/c mice, tumors occurred more 
quickly and grew larger than in non-irradiated animals 
[23]. These findings suggest that cancer is more than just 
a result of epithelial cell proliferation and breaching of 
the basement membrane (invasion). It is a dynamic and 
adaptive phenomenon taking place at the tissue level and 
highlights the importance of addressing the composition 
and quality of the stroma including the ECM. An emerging 
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concept suggests that an altered tissue architecture is in 
fact the core of carcinogenesis [24].
As type I collagen is found in many tissues, and 
as C1M is a circulating fragment of it, it remains to 
be established whether C1M is derived solely from 
local tumor tissue remodeling or from a more systemic 
effect on many tissues and organs. C1M has been found 
elevated in several different diseases characterized by 
ECM remodeling and inflammation and consequently 
it is not specific for cancer [25–31]. This, together with 
the fact that this cohort included women not presenting 
with cancer at time of blood sampling, could indicate 
that high levels of C1M are indicative of an more general 
unhealthy phenotype, that is, with excessive interstitial 
matrix remodeling. The present findings could enable 
one to argue that this unhealthy phenotype could be an 
underlying and under-recognized mechanism in cancer 
leading to a poor prognosis and decreased survival 
following a cancer diagnosis. In support of this, a novel 
paradigm suggests that cancer originates following a 
sequence of events that include chronic inflammation 
and desmoplasia with associated changes in the cellular 
microenvironment [32]. The present data, together with 
the previously published PERF I data showing that 
C1M, C4M, and VICM were associated with increased 
risk of developing cancer [19], supports this notion of 
a role of chronic inflammation and desmoplasia as part 
of tumorgenesis. Thus, ECM and tissue remodeling may 
Table 2: Individual association between biomarkers and common risk factors for cancer, and cancer-specific 
mortality after 3 and 12 years of follow-up for women diagnosed within the first 3 years from baseline 
Variable
3-year follow-up 12-year follow-up
n (dead/total) HR 95%CI p-value n (dead/
total)
HR 95%CI p-value
C1M
continuous
21.2-32.1 ng/ml, Q1
32.2-42.8 ng/ml, Q2
42.9-63.1 ng/ml, Q3
63.2-372.5 ng/ml, Q4
66/237
1.01
1.00
2.37
2.23
2.49
1.00-1.01
-
1.08-5.18
1.01-4.94
1.13-5.48
0.060
-
0.032
0.049
0.024
121/212
1.00
1.00
1.35
1.31
1.18
0.99-1.01
-
0.81-2.26
0.78-2.20
0.70-2.00
0.397
-
0.252
0.313
0.543
C4M
continuous
26.6-60.0 ng/ml, Q1
60.1-71.8 ng/ml, Q2
71.9-90.0 ng/ml, Q3
90.1-210.6 ng/ml, Q4
66/237
1.00
1.00
1.45
0.79
1.11
0.99-1.01
-
0.76-2.77
0.38-1.64
0.56-2.22
0.722
-
0.263
0.537
0.761
121/212
1.00
1.00
1.12
0.84
0.76
0.99-1.00
-
0.69-1.82
0.51-1.39
0.46-1.27
0.383
-
0.639
0.504
0.301
VICM
continuous
0.7-2.2 ng/ml, Q1
2.3-3.9 ng/ml, Q2
4.0-6.5 ng/ml, Q3
6.6-26.2 ng/ml, Q4
66/237
1.01
1.00
1.54
2.25
3.10
0.99-1.02
-
0.68-3.51
1.06-4.80
1.48-6.49
0.454
-
0.302
0.036
0.003
121/212
1.00
1.00
0.90
1.05
1.37
0.99-1.02
-
0.54-1.52
0.64-1.73
0.85-2.21
0.361
-
0.705
0.839
0.195
Age at baseline 71/249 1.03 0.99-1.07 0.112 129/224 1.04 1.01-1.07 0.007
BMI (≥25) 67/240 0.53 0.33-0.86 0.010 122/215 0.67 0.48-0.98 0.038
Smoking  
(yes/no) 71/249 1.76 1.09-2.85 0.022 129/224 1.48 1.01-2.16 0.045
Alcohol  
(≥7 drinks/week)
71/248 1.13 0.70-1.82 0.620 129/223 1.04 0.71-1.51 0.860
Exercise  
(vs ≥1 time/week)
71/248 0.52 0.33-0.82 0.006 129/223 0.75 0.53-1.07 0.113
Education:
Primary school (Ref.)
High school
University
71/248
1.00
1.37
0.67
-
0.78-2.29
0.21-2.13
-
0.286
0.496
129/223
1.00
1.24
0.53
-
0.82-1.85
0.22-1.31
-
0.307
0.171
Hypertension  
(yes/no) 71/249 0.61 0.19-1.94 0.409 129/224 1.01 0.51-1.98 0.975
Hyperlipidemia  
(yes/no) 70/248 0.59 0.35-1.01 0.053 128/223 0.72 0.50-1.05 0.091
HRT (yes/no) 71/249 0.90 0.51-1.59 0.716 129/224 0.82 0.53-1.26 0.362
A cancer Dx prior 
to PERF1 (yes/no) 71/249 1.45 0.82-2.55 0.204 129/224 1.65 1.08-2.50 0.020
Hazard ratios (HR) were calculated by univariable analysis. Biomarkers were analyzed on both a continuous scale and divided into quartiles with the lower quartile (Q1) used 
as a reference to calculate the HR for women in the three upper quartiles (Q2-Q4). All risk factors, except for age, were analyzed on a binominal scale. BMI = body mass index; 
HRT = hormone replacement therapy; Dx = diagnosis.
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be associated with a pre-disposition of being diagnosed 
with a cancer later in life, and consequently affecting 
the survival, as the tumor microenvironment is more 
permissive of cancer development and progression. 
A better outcome for cancer patients might be achieved 
by reversing the underlying mechanisms that result in 
high levels of ECM turnover and tissue remodeling. In 
fact, in a study of rheumatoid arthritis [27], a treatment-
induced decrease in C1M levels by >35 % was 
associated with a lack of disease progression. Whether 
similar findings will be seen in cancer patients remain 
to be established.
Other serum biomarkers of ECM turnover and tissue 
remodeling have been linked with mortality. Although 
not focusing solely on women diagnosed with cancer, 
high serum levels of endostatin, a fragment of type XVIII 
collagen, have been found to be associated with increased 
mortality risk in two independent cohorts of elderly 
people with a follow-up of 8 and 9 years, respectively 
[33]. Likewise, although not focusing on elderly people, 
elevated plasma levels of YKL-40, a protein that is thought 
to play a role in inflammation and tissue remodeling, have 
been shown to predict increased mortality risk during 14 
years of follow-up of women diagnosed with cancer [34].
The current study had some limitations. The cohort 
consisted of elderly Danish postmenopausal women, and 
it is yet to be investigated whether these results would 
be seen in other ages, gender and ethnic groups. Women 
who volunteer for epidemiological studies may over-
represent the proportion of relatively healthy subjects in 
the general population and may bias the findings, albeit in 
favor of rejecting our hypothesis. As some of the baseline 
characteristics (e.g. smoking habits) were collected from 
self-reported questionnaires this may introduce a response/
recall bias, however this is minimized by using current 
status of the patients (e.g. current smoking status). In 
the current study, multiple cancer types with unknown 
medical history were included. It is above the scope of 
the present study to investigate individual cancer types in 
relation to mortality. Still, it is important to recognize that 
the apparent prognostic effect of C1M may be influenced 
by cancer type, specific treatment regimens and history of 
intervention. The contribution of co-morbidities remains 
to be determined and although C1M seems to have 
prognostic value, the true clinical utility of C1M remains 
to be established.
In conclusion, we have shown that C1M and 
VICM are associated with survival over time in elderly 
women who are diagnosed with cancer up to 3 years after 
blood sampling. Moreover, C1M is an independent risk 
factor for cancer-specific mortality. Women with high 
baseline levels of C1M who were diagnosed with cancer 
within 3 years of blood sampling had approximately 
3-fold increased risk of death within the first 3 years of 
Figure 2: Independent predictive value of C1M, C4M and VICM for cancer-specific mortality at 3 and 12 years follow-
up. Hazard ratios (HR) with 95% confidence intervals (95% CI) for cancer-specific mortality in quartiles (Q1–Q4) of C1M, C4M and 
VICM are shown. Values are adjusted for age, BMI, smoking status, alcohol consumption, exercise level, educational level, hypertension, 
hyperlipidemia, use of HRT, and history of cancer.
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Figure 3: Percentage of women surviving cancer at 3 and 12 years follow-up, by C1M, C4M and VICM biomarker 
levels at baseline. Kaplan-Meier survival curves illustrated the percent survival over time for women with baseline biomarker levels in 
the upper quartile (Q4) vs the lower quartile (Q1). A log-rank test was used to determine differences between the survival curves. Curves 
considered significantly different if p<0.05.
Table 3: Independent association between biomarkers and common risk factors for cancer, and cancer-specific 
mortality after 3 and 12 years of follow-up for women diagnosed within the first 3 years from baseline 
Variable
3-year follow-up 12-year follow-up
n (dead/total) HR 95%CI p-value n (dead/total) HR 95%CI p-value
C1M
21.2-32.1 ng/ml, Q1
32.2-42.8 ng/ml, Q2
42.9-63.1 ng/ml, Q3
63.2-372.5 ng/ml, Q4
63/230
1.00
1.81
2.23
2.65
-
0.80-4.10
0.97-5.13
1.08-6.51
-
0.153
0.061
0.035
117/205
1.00
1.18
1.46
1.27
-
0.68-2.05
0.83-2.58
0.69-2.33
-
0.564
0.193
0.440
C4M
26.6-60.0 ng/ml, Q1
60.1-71.8 ng/ml, Q2
71.9-90.0 ng/ml, Q3
90.1-210.6 ng/ml, Q4
1.00
0.92
0.65
0.72
-
0.44-1.91
0.29-1.44
0.31-1.63
-
0.816
0.289
0.426
1.00
0.73
0.76
0.61
-
0.42-1.27
0.44-1.31
0.35-1.09
-
0.269
0.327
0.095
VICM
0.7-2.2 ng/ml, Q1
2.3-3.9 ng/ml, Q2
4.0-6.5 ng/ml, Q3
6.6-26.2 ng/ml, Q4
1.00
0.91
1.03
1.10
-
0.52-1.59
0.59-1.78
0.64-1.88
-
0.736
0.928
0.741
1.00
0.60
0.61
0.58
-
0.36-1.01
0.35-1.06
0.34-1.02
-
0.053
0.078
0.060
Age at baseline 1.02 0.98-1.06 0.331 1.04 1.01-1.08 0.018
BMI (≥25) 0.56 0.33-0.95 0.032 0.69 0.47-1.01 0.058
Smoking  
(yes/no) 1.61 0.91-2.84 0.105 1.31 0.84-2.06 0.228
Alcohol  
(≥7 drinks/week)
1.00 0.58-1.72 0.999 1.00 0.67-1.47 0.994
Exercise  
(vs ≥1 time/week)
0.54 0.30-0.91 0.021 0.79 0.53-1.19 0.269
Education:
Primary school (Ref.)
High school
University
1.00
1.24
0.89
-
0.65-2.38
0.26-3.05
-
0.515
0.853
1.00
1.11
0.62
-
0.69-1.80
0.24-1.59
-
0.660
0.319
Hypertension  
(yes/no) 0.60 0.17-2.04 0.412 0.80 0.37-1.78 0.601
Hyperlipidemia 
(yes/no) 0.51 0.28-0.94 0.032 0.66 0.43-1.01 0.058
HRT (yes/no) 0.83 0.44-1.55 0.349 0.74 0.46-1.19 0.223
A cancer Dx prior 
to PERF1  
(yes/no)
1.12 0.58-2.16 0.730 1.51 0.94-2.43 0.088
Hazard ratios (HR) were calculated by multivariate analysis. Biomarkers were analyzed on both a continuous scale and divided into quartiles with the lower quartile (Q1) used 
as a reference to calculate the HR for women in the three upper quartiles (Q2-Q4). All risk factors except for age were analyzed on a binominal scale. BMI = body mass index; 
HRT = hormone replacement therapy; Dx = diagnosis.
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follow-up compared with those with low baseline C1M 
levels. This supports the potential of C1M and VICM as 
biomarkers of a poor short-term outcome in cancer and 
underlines the importance of measuring altered ECM and 
tissue remodeling to understand the development and 
progression of this disease.
MATERIALS AND METHODS
Study design and participants
Between 1999 and 2001, a total of 5855 
postmenopausal Danish women aged 60-85 participated 
in the PERF I, an observational, prospective cohort study 
aiming to identify risk factors associated with age-related 
diseases [18]. All subjects were derived from a database 
(n=8875) of postmenopausal women previously invited to 
participate in clinical trials at the Center for Clinical and 
Basic Research (CCBR) in Copenhagen or Aalborg. To 
ensure that no overrepresentation of women with a history 
of any specific diseases occurred, all women in the CCBR 
database were invited irrespective of previous medical 
history. A total of 5855 women volunteered to participate 
in PERF I. The study was approved by the local ethics 
committees and carried out in accordance with ICH-GCP 
and the Helsinki declaration. Informed consents were 
obtained from all individual participants.
Baseline investigations
A fasting venous blood sample was drawn at the 
PERF I baseline visit. A self-reported questionnaire was 
used with standardized methods to capture demographic 
and other baseline data including age, body mass index 
(BMI), current smoking habits, socioeconomic status, 
medical history, physical activity level, current alcohol 
intake, and level of education.
Cancer diagnoses
Cancer diagnoses were collected from the Danish 
Cancer Registry in December 2014 in which the last 
diagnosis was registered in December 2012. Diagnoses 
were classified according to the International Statistical 
Classification of Diseases (ICD). Diagnoses were based on 
ICD10 between 1977 and 2012, and ICD7 for the period 
prior to 1977. Only women diagnosed with cancer 0-3 
years after baseline were included in the analyses. Women 
with only benign neoplasms (D10-D36), neoplasms 
of uncertain or unknown behavior (D37-D48), non-
melanoma skin cancer (C44, D040-D049), dysplasia 
(N87), malignant neoplasms stated or presumed to be 
primary, of lymphoid, hematopoietic and related tissue 
(C81-C96), and any successive combination of only 
those diagnoses were excluded from the group of women 
diagnosed with cancer.
Serum biomarkers analysis
A central CAP-certified laboratory measured 
levels of MMP-degraded type I collagen (C1M), MMP-
degraded type IV collagen (C4M) and MMP-degraded 
citrullianted vimentin (VICM) in serum using competitive 
enzyme-linked immune sorbent assays (ELISAs). Assays 
measuring C1M, C4M and VICM, which each have 
a specific MMP-generated neoepitope present, were 
originally described and validated by Leeming et al [9], 
Sand et al [10], and Vassiliadis et al [14], respectively. 
Technically, the intra- and inter-assay variations are <10 
% and <15 % for these assays. Levels of biomarkers 
were determined in duplicates in samples stored for 
approximately 12 years at -80°C. Women missing 
biomarker measurements were excluded from the analysis.
Primary end-point (outcome variable)
Cancer-specific mortality (using ICD10 codes 
C00-D48) was the primary end-point. Data on cause and 
time of death up to 1 January 2013 were collected from the 
National Danish Causes of Death Registry and The Danish 
Civil Registration System, respectively. Causes of death 
(CoD) were classified according to ICD10. Deaths due 
to any causes other than cancer (ICD10 codes D50-U85) 
were excluded from the risk analysis. Total survival time 
was defined as years from enrollment in PERF 1 until date 
of death or being alive at 1 January 2013. The average 
follow-up was 12.1 years.
Risk factors (other variables)
The primary risk factors were serum C1M, C4M and 
VICM levels. Secondary risk factors assessed at baseline 
included age, BMI (≥25), smoking (current, yes/no), 
alcohol consumption (current, ≥7 drinks/week), exercise 
(≥1 time/week), education (primary school, high school, 
university), hypertension (current, yes/no), hyperlipidemia 
(current, yes/no), use of hormone replacement therapy 
(HRT) (current, yes/no).
Statistical analysis
Baseline characteristics of deceased women and 
survivors were compared using either a Mann–Whitney 
U test for numerical values or a Chi-square test for 
categorical values.
Univariable Cox proportional-hazards regression 
models were used to calculate hazard ratios (HRs) with 
95% confidence intervals (95% CI) for cancer-specific 
mortality for the primary and secondary risk factors for 
cancer: C1M, C4M, VICM, age, BMI, smoking status, 
alcohol intake, exercise, level of education, hypertension, 
hyperlipidemia, use of HRT. To assess any confounding 
effects, a multivariable Cox proportional-hazard regression 
model was used to calculate the independent HR with 95% 
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CI for cancer-specific mortality including the primary and 
secondary risk factors and also adjusted in cases where 
cancer was diagnosed before PERF I enrollment. Baseline 
biomarker levels in the lowest quartile (Q1) were used as 
a reference to calculate the HRs for women with baseline 
biomarkers levels in the three upper quartiles (Q2-Q4). 
Univariable analysis also included HRs for C1M, C4M 
and VICM on a continuous scale. The time-to-mortality 
intervals analyzed were 0-3 years and 0-12 years from 
blood sampling.
Kaplan-Meier survival curves were used to analyze 
mortality over time in the lowest (Q1) and highest (Q4) 
quartiles. A log-rank test was used to determine differences 
between curves.
Statistical analysis was conducted using MedCalc® 
(v12.3.0). Data were considered statistically different 
when p<0.05.
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